Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 8.9% | -8.9% | 15.1% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 88.2% | 86.2% | 86.9% | 87.1% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 26.9% | 14.8% | 23% | 22.3% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 11.2% | 0.2% | 9.1% | 9.2% |
| EPS Diluted | 1.32 | 0.024 | 1.04 | 0.98 |
| % Growth | 5,469.6% | -97.7% | 6.1% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |